Statins in heart failure: do we need another trial?

被引：24

作者：

Bonsu, Kwadwo Osei ^{[1
]}

Kadirvelu, Amudha ^{[1
]}

Reidpath, Daniel Diamond ^{[1
]}

机构：

[1] Monash Univ, Sch Med & Hlth Sci, Sunway Campus,Jalan Lagoon Selatan, Bandar Sunway 46150, Selangor DE, Malaysia

来源：

VASCULAR HEALTH AND RISK MANAGEMENT | 2013年 / 9卷

关键词：

statins; treatment; heart failure; comorbidity; mortality;

D O I：

10.2147/VHRM.S44499

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Statins lower serum cholesterol and are employed for primary and secondary prevention of cardiovascular events. Clinical evidence from observational studies, retrospective data, and post hoc analyses of data from large statin trials in various cardiovascular conditions, as well as small scale randomized trials, suggest survival and other outcome benefits for heart failure. Two recent large randomized controlled trials, however, appear to suggest statins do not have beneficial effects in heart failure. In addition to lowering cholesterol, statins are believed to have many pleotropic effects which could possibly influence the pathophysiology of heart failure. Following the two large trials, evidence from recent studies appears to support the use of statins in heart failure. This review discusses the role of statins in the pathophysiology of heart failure, current evidence for statin use in heart failure, and suggests directions for future research.

引用

页码：303 / 319

页数：17

共 154 条

[1] Role of Rac1 GTPase activation in atrial fibrillation [J].

Adam, Oliver ;

Frost, Gregg ;

Custodis, Florian ;

Sussman, Mark A. ;

Schaefers, Hans-Joachim ;

Boehm, Michael ;

Laufs, Ulrich .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (04) :359-367

[2]

Aikawa M, 2001, CIRCULATION, V103, P276

[3] Short-Term Effect of Atorvastatin on Endothelial Function in Healthy Offspring of Parents with Type 2 Diabetes Mellitus [J].

Amudha, Kadirvelu ;

Choy, Anna Maria ;

Mustafa, Mohamed R. ;

Lang, Chim C. .

CARDIOVASCULAR THERAPEUTICS, 2008, 26 (04) :253-261

[4] Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: A randomized placebo-controlled study [J].

Andreou, Ioannis ;

Tousoulis, Dimitris ;

Miliou, Antigoni ;

Tentolouris, Costas ;

Zisimos, Kostas ;

Gounari, Panagiota ;

Siasos, Gerasimos ;

Papageorgiou, Nikos ;

Papadimitriou, Christos A. ;

Dimopoulos, Meletios-Athanasios ;

Stefanadis, Christodoulos .

ATHEROSCLEROSIS, 2010, 210 (01) :194-198

[5] Uric acid and survival in chronic heart failure - Validation and application in metabolic, functional, and Hemodynamic staging [J].

Anker, SD ;

Doehner, W ;

Rauchhaus, M ;

Sharma, R ;

Francis, D ;

Knosalla, C ;

Davos, CH ;

Cicoira, M ;

Shamim, W ;

Kemp, M ;

Segal, R ;

Osterziel, KJ ;

Leyva, F ;

Hetzer, R ;

Ponikowski, P ;

Coats, AJS .

CIRCULATION, 2003, 107 (15) :1991-1997

[6] Statin use and survival in patients with chronic heart failure - results from two observational studies with 5200 patients [J].

Anker, Stefan D. ;

Clark, Andrew L. ;

Winkler, Ralf ;

Zugck, Christian ;

Cicoira, Mariantonietta ;

Ponikowski, Piotr ;

Davos, Constantinos H. ;

Banasiak, Waldemar ;

Zardini, Piero ;

Haass, Markus ;

Senges, Jochen ;

Coats, Andrew J. S. ;

Poole-Wilson, Philip A. ;

Pitt, Bertram .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 112 (02) :234-242

[7] Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary heart-disease Evaluation (GREACE) Study [J].

Athyros, VG ;

Mikhailidis, DP ;

Papageorgiou, AA ;

Symeonidis, AN ;

Mercouris, BR ;

Pehlivanidis, AN ;

Bouloukos, VI ;

Elisaf, M .

CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (05) :627-637

[8] Pathogenesis and treatment of kidney disease and hypertension - Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study [J].

Athyros, VG ;

Elisaf, M ;

Papageorgiou, AA ;

Symeonidis, AN ;

Pehlivanidis, AN ;

Bouloukos, VI ;

Milionis, HJ ;

Mikhailidis, DP .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (04) :589-599

[9]

Bauersachs J, 2008, PHARMACOL REP, V60, P119

[10] HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages [J].

Bellosta, S ;

Via, D ;

Canavesi, M ;

Pfister, P ;

Fumagalli, R ;

Paoletti, R ;

Bernini, F .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (11) :1671-1678

← 1 2 3 4 5 6 7 8 9 10 →